SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Sector | Business Services |
| Employees | 1,050 |
| Revenue | 64M GBP (2024) |
Syncona is a healthcare company focused on founding, building and funding global leaders in life science. Syncona focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Syncona is based in London, United Kingdom.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 2 |
| Sector (Life Science) | 1 of 2 |
| Type (Add-on Acquisition) | 1 of 2 |
| State (Florida) | 1 of 1 |
| Country (United States) | 1 of 1 |
| Year (2022) | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-02-12 |
Freeline
Stevenage, United Kingdom Freeline is a clinical-stage biotechnology company focused on developing transformative gene therapies for chronic debilitating diseases. Freeline uses its proprietary, rationally designed AAV vector and capsid (AAVS3), along with novel promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing or dysfunctional protein into a patient’s bloodstream. The company is currently advancing FLT201, a highly differentiated gene therapy candidate that delivers a novel transgene, in a Phase 1/2 clinical trial in people with Gaucher disease type 1. It has additional programs in research, including one focused on GBA1-linked Parkinson’s disease that leverages the same novel transgene as FLT201. Freeline is headquartered in Stevenage, UK, and has operations in the United States. |
Buy | - |
